# American Journal of Clinical Dermatology

**Type:** Journals  
**Canonical URL:** https://scholariq.org/journals/american-journal-of-clinical-dermatology/

## Facts

| Field | Value |
| --- | --- |
| Open Access | false |
| ISSN-L | 1175-0561 |
| ISSNs | 1175-0561,1179-1888 |
| OpenAlex ID | https://openalex.org/S71020152 |
| Publisher | Adis, Springer Healthcare |

## Journal papers

Showing 12 of 17.

- [The Psychosocial Burden of Psoriasis](https://scholariq.org/papers/the-psychosocial-burden-of-psoriasis/)
- [The Role of Hyaluronic Acid in Wound Healing](https://scholariq.org/papers/the-role-of-hyaluronic-acid-in-wound-healing/)
- [Natural Oils for Skin-Barrier Repair: Ancient Compounds Now Backed by Modern Science](https://scholariq.org/papers/natural-oils-for-skin-barrier-repair-ancient-compounds-now-backed-by-modern/)
- [Artificial Intelligence in Dermatology—Where We Are and the Way to the Future: A Review](https://scholariq.org/papers/artificial-intelligence-in-dermatology-where-we-are-and-the-way-to-the-future-a/)
- [Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program](https://scholariq.org/papers/integrated-safety-analysis-of-abrocitinib-for-the-treatment-of-moderate-to/)
- [Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib](https://scholariq.org/papers/selective-jak1-inhibitors-for-the-treatment-of-atopic-dermatitis-focus-on/)
- [Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study](https://scholariq.org/papers/drug-survival-of-il-12-23-il-17-and-il-23-inhibitors-for-psoriasis-treatment-a/)
- [Palmoplantar Psoriasis and Palmoplantar Pustulosis: Current Treatment and Future Prospects](https://scholariq.org/papers/palmoplantar-psoriasis-and-palmoplantar-pustulosis-current-treatment-and-future/)
- [Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis](https://scholariq.org/papers/apremilast-a-novel-oral-treatment-for-psoriasis-and-psoriatic-arthritis/)
- [Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1)](https://scholariq.org/papers/safety-effectiveness-and-pharmacokinetics-of-crisaborole-in-infants-aged-3-to/)
- [Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review](https://scholariq.org/papers/time-to-relapse-after-discontinuing-systemic-treatment-for-psoriasis-a/)
- [Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial](https://scholariq.org/papers/clinically-meaningful-responses-to-dupilumab-in-adolescents-with-uncontrolled/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.